Evidence map›Paper›PMID 38167986›Full record

ArticleScientific reports2024

Filling knowledge gaps related to AmpC-dependent β-lactam resistance in Enterobacter cloacae.

Isabel M Barceló, María Escobar-Salom, Elena Jordana-Lluch, Gabriel Torrens, Antonio Oliver, Carlos Juan

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Genomic analysis ofMicrobial genomics · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Bacterial peptidoglycan as a living polymer.Current opinion in chemical biology · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Microbiology spectrum · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Isabel M Barceló *Health Research Institute of the Balearic Islands (IdISBa), 07010, Palma, Spain.
María Escobar-Salom *Health Research Institute of the Balearic Islands (IdISBa), 07010, Palma, Spain.
Elena Jordana-LluchHealth Research Institute of the Balearic Islands (IdISBa), 07010, Palma, Spain.
Gabriel TorrensDepartment of Molecular Biology and Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå Centre for Microbial Research (UCMR), Umeå University, 901 87, Umeå, Sweden.
Antonio OliverHealth Research Institute of the Balearic Islands (IdISBa), 07010, Palma, Spain.
Carlos JuanHealth Research Institute of the Balearic Islands (IdISBa), 07010, Palma, Spain. carlos.juan@ssib.es.
Health Research Institute of the Balearic Islands · ESCentro de Investigación Biomédica en Red · ESInstituto de Salud Carlos III · ESUmeå University · SE

Funding

Direcció General de Política Universitària i Recerca, Govern Illes Balears FPI/2206/2019Govern de les Illes Balears FOLIUM17/04Instituto de Salud Carlos III CPII17/00017Instituto de Salud Carlos III FI19/00004Instituto de Salud Carlos III RD16/0016/0004Ministerio de Ciencia e Innovación IJC2019-038836-I
6 · The paper itself

Abstract

Enterobacter cloacae starred different pioneer studies that enabled the development of a widely accepted model for the peptidoglycan metabolism-linked regulation of intrinsic class C cephalosporinases, highly conserved in different Gram-negatives. However, some mechanistic and fitness/virulence-related aspects of E. cloacae choromosomal AmpC-dependent resistance are not completely understood. The present study including knockout mutants, β-lactamase cloning, gene expression analysis, characterization of resistance phenotypes, and the Galleria mellonella infection model fills these gaps demonstrating that: (i) AmpC enzyme does not show any collateral activity impacting fitness/virulence; (ii) AmpC hyperproduction mediated by ampD inactivation does not entail any biological cost; (iii) alteration of peptidoglycan recycling alone or combined with AmpC hyperproduction causes no attenuation of E. cloacae virulence in contrast to other species; (iv) derepression of E. cloacae AmpC does not follow a stepwise dynamics linked to the sequential inactivation of AmpD amidase homologues as happens in Pseudomonas aeruginosa; (v) the enigmatic additional putative AmpC-type β-lactamase generally present in E. cloacae does not contribute to the classical cephalosporinase hyperproduction-based resistance, having a negligible impact on phenotypes even when hyperproduced from multicopy vector. This study reveals interesting particularities in the chromosomal AmpC-related behavior of E. cloacae that complete the knowledge on this top resistance mechanism.

Indexed as

Enterobacter cloacaePeptidoglycanBacterial Proteinsbeta-Lactamasesbeta-Lactam ResistanceCephalosporinaseMicrobial Sensitivity TestsBacterial Proteinsbeta-LactamasesCephalosporinasePeptidoglycan

Identifiers

PMID38167986
PMCPMC10762043
OpenAlexW4390500302

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.